Federal Circuit Strikes Down Diagnostic Patent in Latest § 101 DecisionMay 14, 2019
On February 6, 2019, the Federal Circuit issued its latest opinion on patentable subject matter in the life sciences under 35 U.S.C. § 101 in Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, No. 2017-2508, slip. Op. (Fed. Cir. Feb. 6, 2019). Judge Lourie wrote for the majority in this split decision, expressing some regret but affirming an order invalidating a diagnostic patent involving proteins. Judge Newman dissented, voicing a concern that § 101 jurisprudence has become counterproductive to the goals of patent law. Though unsurprising, the decision further narrows an already shrinking space for patents to diagnostic methods. It is unclear from this decision what diagnostic methods, if any, are safe from future § 101 challenges.
To continue reading Jordan Engelhardt and Dorothy LeRay's article from IP Litigator, please click here.